Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020 Regeneron Pharmaceuticals, Inc ...

Lack of insurance coverage continues to be the most commonly cited barrier to use, while out-of-pocket costs have become a growing concern amongst dermatologists. Those with ample experience with the ...